Related references
Note: Only part of the references are listed.Development of Tetravalent, Bispecific CCR5 Antibodies with Antiviral Activity against CCR5 Monoclonal Antibody-Resistant HIV-1 Strains
Juergen Schanzer et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Emerging therapies for severe asthma
Neil C. Thomson et al.
BMC MEDICINE (2011)
The Bs20x22 anti-CD20-CD22 bispecific antibody has more lymphomacidal activity than do the parent antibodies alone
Joseph M. Tuscano et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2011)
Preclinical Pharmacokinetics and Safety of Sym004: A Synergistic Antibody Mixture Directed against Epidermal Growth Factor Receptor
Niels Jorgen Ostergaard Skartved et al.
CLINICAL CANCER RESEARCH (2011)
A Phase 1 Study of AS1409, a Novel Antibody-Cytokine Fusion Protein, in Patients with Malignant Melanoma or Renal Cell Carcinoma
Sarah M. Rudman et al.
CLINICAL CANCER RESEARCH (2011)
Therapeutic potential of anticancer immunotoxins
Swati Choudhary et al.
DRUG DISCOVERY TODAY (2011)
Stable IgG-like Bispecific Antibodies Directed toward the Type I Insulin-like Growth Factor Receptor Demonstrate Enhanced Ligand Blockade and Anti-tumor Activity
Jianying Dong et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Targeted Therapy With the T-Cell-Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival
Max S. Topp et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
A novel bispecific ligand-directed toxin designed to simultaneously target EGFR on human glioblastoma cells and uPAR on tumor neovasculature
Alexander K. Tsai et al.
JOURNAL OF NEURO-ONCOLOGY (2011)
Vascular endothelial growth factors and receptors: Anti-angiogenic therapy in the treatment of cancer
Sonia Tugues et al.
MOLECULAR ASPECTS OF MEDICINE (2011)
Emerging antibody combinations in oncology
Stephen J. Demarest et al.
MABS (2011)
A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activity
Jianying Dong et al.
MABS (2011)
A fibronectin scaffold approach to bispecific inhibitors of epidermal growth factor receptor and insulin-like growth factor-I receptor
Stuart L. Emanuel et al.
MABS (2011)
A single-chain triplebody with specificity for CD19 and CD33 mediates effective lysis of mixed lineage leukemia cells by dual targeting
Ingo Schubert et al.
MABS (2011)
A novel bispecific antibody format enables simultaneous bivalent and monovalent co-engagement of distinct target antigens
Gregory L. Moore et al.
MABS (2011)
Antibody-based therapeutics to watch in 2011
Janice M. Reichert
MABS (2011)
Recombinant proteins in rheumatology - recent advances
Achim Rothe et al.
NEW BIOTECHNOLOGY (2011)
Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes
Masanori Onda et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies
Wolfgang Schaefer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Heavy chain-only antibodies and tetravalent bispecific antibody neutralizing Staphylococcus aureus leukotoxins
Benoit-Joseph Laventie et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Pegylated liposomal doxorubicin: appraisal of its current role in the management of epithelial ovarian cancer
Maurie Markman
Cancer Management and Research (2011)
Targeting the B Cell in Rheumatoid Arthritis
Stanley B. Cohen
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY (2010)
Bispecific Antibodies for Cancer Immunotherapy
Dafne Müller et al.
BIODRUGS (2010)
Multiple signaling pathways induced by hexavalent, monospecific, anti-CD20 and hexavalent, bispecific, anti-CD20/CD22 humanized antibodies correlate with enhanced toxicity to B-cell lymphomas and leukemias
Pankaj Gupta et al.
BLOOD (2010)
A recombinant trispecific single-chain Fv derivative directed against CD123 and CD33 mediates effective elimination of acute myeloid leukaemia cells by dual targeting
Markus Kuegler et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
A bispecific antibody effectively inhibits tumor growth and metastasis by simultaneous blocking vascular endothelial growth factor A and osteopontin
Geng Kou et al.
CANCER LETTERS (2010)
A novel DDS strategy, dual-targeting, and its application for antineovascular therapy
Yuki Murase et al.
CANCER LETTERS (2010)
MM-111: a novel bispecific antibody targeting ErbB3 with potent anti-tumor activity in ErbB2 over-expressing malignancies.
U Nielsen et al.
CANCER RESEARCH (2010)
A Bispecific Antibody-IFNα2b Immunocytokine Targeting CD20 and HLA-DR Is Highly Toxic to Human Lymphoma and Multiple Myeloma Cells
Edmund A. Rossi et al.
CANCER RESEARCH (2010)
Sym004: A Novel Synergistic Anti-Epidermal Growth Factor Receptor Antibody Mixture with Superior Anticancer Efficacy
Mikkel Wandahl Pedersen et al.
CANCER RESEARCH (2010)
Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy
Diane Seimetz et al.
CANCER TREATMENT REVIEWS (2010)
A bispecific nanobody to provide full protection against lethal scorpion envenoming
Issam Hmila et al.
FASEB JOURNAL (2010)
Development of a Two-part Strategy to Identify a Therapeutic Human Bispecific Antibody That Inhibits IgE Receptor Signaling
Janet Jackman et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Enhancing Antibody Fc Heterodimer Formation through Electrostatic Steering Effects APPLICATIONS TO BISPECIFIC MOLECULES AND MONOVALENT IgG
Kannan Gunasekaran et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Effector Cell Recruitment with Novel Fv-based Dual-affinity Re-targeting Protein Leads to Potent Tumor Cytolysis and in Vivo B-cell Depletion
Syd Johnson et al.
JOURNAL OF MOLECULAR BIOLOGY (2010)
Combination of Two Insulin-Like Growth Factor-I Receptor Inhibitory Antibodies Targeting Distinct Epitopes Leads to an Enhanced Antitumor Response
Jianying Dong et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Bioengineering a Unique Deimmunized Bispecific Targeted Toxin That Simultaneously Recognizes Human CD22 and CD19 Receptors in a Mouse Model of B-Cell Metastases
Daniel A. Vallera et al.
MOLECULAR CANCER THERAPEUTICS (2010)
A dual-targeting PDGFR beta/VEGF-A molecule assembled from stable antibody fragments demonstrates anti-angiogenic activity in vitro and in vivo
Robert Mabry et al.
MABS (2010)
Synergistic Targeting of alpha(v)beta(3) Integrin and Galectin-1 with Heteromultivalent Paramagnetic Liposomes for Combined MR Imaging and Treatment of Angiogenesis
Ewelina Kluza et al.
NANO LETTERS (2010)
Enhanced antitumor effect of novel dual-targeted paclitaxel liposomes
Shuyan Meng et al.
NANOTECHNOLOGY (2010)
Development trends for human monoclonal antibody therapeutics
Aaron L. Nelson et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
A New Drug Delivery Method of Bispecific Ligand-Directed Toxins, Which Reduces Toxicity and Promotes Efficacy in a Model of Orthotopic Pancreatic Cancer
Seunguk Oh et al.
PANCREAS (2010)
Chemical generation of bispecific antibodies
Venkata R. Doppalapudi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Engineering of stable bispecific antibodies targeting IL-17A and IL-23
Robert Mabry et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2010)
A modular IgG-scFv bispecific antibody topology
Kelly Davis Orcutt et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2010)
Introducing antigen-binding sites in structural loops of immunoglobulin constant domains: Fc fragments with engineered HER2/neu-binding sites and antibody properties
G. Wozniak-Knopp et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2010)
SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies
Jonathan H. Davis et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2010)
Fc gamma RIIB in autoimmunity and infection: evolutionary and therapeutic implications
Kenneth G. C. Smith et al.
NATURE REVIEWS IMMUNOLOGY (2010)
Therapeutic antibodies for autoimmunity and inflammation
Andrew C. Chan et al.
NATURE REVIEWS IMMUNOLOGY (2010)
Fc gamma RIIB in autoimmunity and infection: evolutionary and therapeutic implications (vol 10, pg 328, 2010)
Kenneth G. C. Smith et al.
NATURE REVIEWS IMMUNOLOGY (2010)
High coexpression of both insulin-like growth factor receptor-1 (IGFR-1) and epidermal growth factor receptor (EGFR) is associated with shorter disease-free survival in resected non-small-cell lung cancer patients
V. Ludovini et al.
ANNALS OF ONCOLOGY (2009)
Immune Therapy for Cancer
Michael Dougan et al.
ANNUAL REVIEW OF IMMUNOLOGY (2009)
Strategies to Extend Plasma Half-Lives of Recombinant Antibodies
Roland E. Kontermann
BIODRUGS (2009)
Engineering and characterization of a bispecific HER2 x EGFR-binding affibody molecule
Mikaela Friedman et al.
BIOTECHNOLOGY AND APPLIED BIOCHEMISTRY (2009)
Hexavalent bispecific antibodies represent a new class of anticancer therapeutics: 1. Properties of anti-CD20/CD22 antibodies in lymphoma
Edmund A. Rossi et al.
BLOOD (2009)
Design and modification of EGF4KDEL 7Mut, a novel bispecific ligand-directed toxin, with decreased immunogenicity and potent anti-mesothelioma activity
B. J. Stish et al.
BRITISH JOURNAL OF CANCER (2009)
A Novel Reduced Immunogenicity Bispecific Targeted Toxin Simultaneously Recognizing Human Epidermal Growth Factor and Interleukin-4 Receptors in a Mouse Model of Metastatic Breast Carcinoma
Seunguk Oh et al.
CLINICAL CANCER RESEARCH (2009)
Crosstalk Between Epidermal Growth Factor Receptor- and Insulin-Like Growth Factor-1 Receptor Signaling: Implications for Cancer Therapy
J. Veeken et al.
CURRENT CANCER DRUG TARGETS (2009)
Denileukin diftitox: a novel immunotoxin
George Manoukian et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2009)
DARPins as Bispecific Receptor Antagonists Analyzed for Immunoglobulin E Receptor Blockage
Alexander Eggel et al.
JOURNAL OF MOLECULAR BIOLOGY (2009)
Intracranial elimination of human glioblastoma brain tumors in nude rats using the bispecific ligand-directed toxin, DTEGF13 and convection enhanced delivery
Seunguk Oh et al.
JOURNAL OF NEURO-ONCOLOGY (2009)
Bispecific immunotoxins
Arthur E. Frankel et al.
LEUKEMIA RESEARCH (2009)
Genetic alteration of a bispecific ligand-directed toxin targeting human CD19 and CD22 receptors resulting in improved efficacy against systemic B cell malignancy
Daniel A. Vallera et al.
LEUKEMIA RESEARCH (2009)
Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTβR
Jennifer S. Michaelson et al.
MABS (2009)
Molecular construction and optimization of anti-human IL-1α/β dual variable domain immunoglobulin (DVD-Ig™) molecules
Chengbin Wu et al.
MABS (2009)
Dual targeting of a thermosensitive nanogel conjugated with transferrin and RGD-containing peptide for effective cell uptake and drug release
Chang-Yun Quan et al.
NANOTECHNOLOGY (2009)
Variants of the Antibody Herceptin That Interact with HER2 and VEGF at the Antigen Binding Site
Jenny Bostrom et al.
SCIENCE (2009)
Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer
Yogeshkumar Malam et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2009)
Monoclonal antibody-based therapies for microbial diseases
Carolyn Saylor et al.
VACCINE (2009)
Durable Complete Responses From Therapy With Combined Epratuzumab and Rituximab Final Results From an International Multicenter, Phase 2 Study in Recurrent, Indolent, Non-Hodgkin Lymphoma
John P. Leonard et al.
CANCER (2008)
Specific blockade of VEGF and HER2 pathways results in greater growth inhibition of breast cancer xenografts that overexpress HER2
Xiao-Feng Le et al.
CELL CYCLE (2008)
The epidermal growth factor receptor family: Biology driving targeted therapeutics
M. J. Wieduwilt et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2008)
Therapeutic nanoparticles for drug delivery in cancer
Kwangjae Cho et al.
CLINICAL CANCER RESEARCH (2008)
Molecular engineering and design of therapeutic antibodies
Leonard G. Presta
CURRENT OPINION IN IMMUNOLOGY (2008)
Antibody-cytokine fusion proteins:: applications in cancer therapy
Elizabeth Ortiz-Sanchez et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2008)
Antibody-modified liposomes for cancer chemotherapy
Vladimir Torchilin
EXPERT OPINION ON DRUG DELIVERY (2008)
Genetically designing a more potent antipancreatic cancer agent by simultaneously co-targeting human IL13 and EGF receptors in a mouse xenograft model
D. A. Vallera et al.
GUT (2008)
Th17 cell differentiation: The long and winding road
Mandy J. McGeachy et al.
IMMUNITY (2008)
Ligand-based targeting of apoptosis in cancer: The potential of recombinant human apoptosis ligand 2/tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL)
Avi Ashkenazi et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
A Novel CD19-directed Recombinant Bispecific Antibody Derivative With Enhanced Immune Effector Functions for Human Leukemic Cells
Christian Kellner et al.
JOURNAL OF IMMUNOTHERAPY (2008)
Tumor regression in cancer patients by very low doses of a T cell-engaging antibody
Ralf Bargou et al.
SCIENCE (2008)
Anti-glioblastoma effect of a recombinant bispecific cytotoxin cotargeting human IL-13 and EGF receptors in a mouse xenograft model
Brad J. Stish et al.
JOURNAL OF NEURO-ONCOLOGY (2008)
Bispecific anti-CD20/22 antibodies inhibit B-cell lymphoma proliferation by a unique mechanism of action
Zhengxing Qu et al.
BLOOD (2008)
Multifunctional antibodies by the dock-and-lock method for improved cancer Imaging and therapy by pretargeting
David M. Goldenberg et al.
JOURNAL OF NUCLEAR MEDICINE (2008)
Liposomal nanomedicines
David B. Fenske et al.
EXPERT OPINION ON DRUG DELIVERY (2008)
Nanocarriers as an emerging platform for cancer therapy
Dan Peer et al.
NATURE NANOTECHNOLOGY (2007)
Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin
Chengbin Wu et al.
NATURE BIOTECHNOLOGY (2007)
A bispecific recombinant cytotoxin (DTEGF13) targeting human interleukin-13 and epidermal growth factor receptors in a mouse xenograft model of prostate cancer
Brad J. Stish et al.
CLINICAL CANCER RESEARCH (2007)
Mechanisms of disease: signaling of the insulin-like growth factor I receptor pathway-therapeutic perspectives in cancer
Yungan Tao et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2007)
An antibody directed against PDGF receptor β enhances the antitumor and the anti-angiogenic activities of an anti-VEGF receptor 2 antibody
Juqun Shen et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2007)
Increasing anticarcinoma activity of an anti-erbB2 recombinant immunotoxin by the addition of an anti-EpCAM sFv
Brad J. Stish et al.
CLINICAL CANCER RESEARCH (2007)
Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial
Michael Weinblatt et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
Toxicokinetic and toxicodynamic analyses of Androctonus australis hector venom in rats:: Optimization of antivenom therapy
D. Hammoudi-Triki et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2007)
Single variable domain antibody as a versatile building block for the construction of IgG-like bispecific antibodies
Juqun Shen et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2007)
pH-sensitive liposomes - principle and application in cancer therapy
H. Karanth et al.
JOURNAL OF PHARMACY AND PHARMACOLOGY (2007)
Human domain antibodies against virulence traits of Candida albicans inhibit fungus adherence to vaginal epithelium and protect against experimental vaginal candidiasis
Flavia De Bernardis et al.
JOURNAL OF INFECTIOUS DISEASES (2007)
Immunotoxin treatment of cancer
Ira Pastan et al.
ANNUAL REVIEW OF MEDICINE (2007)
Growth factor receptor interplay and resistance in cancer
Helen E. Jones et al.
ENDOCRINE-RELATED CANCER (2006)
Management of asthma with anti-immunoglobulin E: A review of clinical trials of omalizumab
Dennis Nowak
RESPIRATORY MEDICINE (2006)
B cell depletion therapy in rheumatic disease
J. C. W. Edwards et al.
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY (2006)
A dual-ligand approach for enhancing targeting selectivity of therapeutic nanocarriers
Justin M. Saul et al.
JOURNAL OF CONTROLLED RELEASE (2006)
Engineering of therapeutic antibodies to minimize immunogenicity and optimize function
Leonard G. Presta
ADVANCED DRUG DELIVERY REVIEWS (2006)
Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models
Dmitri B. Kirpotin et al.
CANCER RESEARCH (2006)
Recombinant polyclonal antibodies: the next generation of antibody therapeutics?
John S. Haurum
DRUG DISCOVERY TODAY (2006)
Immunotoxin pharmacokinetics: a comparison of the anti-glioblastoma bi-specific fusion protein (DTAT13) to DTAT and DTIL13
Edward Rustamzadeh et al.
JOURNAL OF NEURO-ONCOLOGY (2006)
Single variable domain-IgG fusion - A novel recombinant approach to Fc domain-containing bispecific antibodies
JQ Shen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Preclinical manufacture of an anti-HER2 scFv-PEG-DSPE, liposome-inserting conjugate. 1. Gram-scale production and purification
DF Nellis et al.
BIOTECHNOLOGY PROGRESS (2005)
Resistance to epidermal growth factor receptor-targeted therapy
F Morgillo et al.
DRUG RESISTANCE UPDATES (2005)
Liposomes targeted via two different antibodies: Assay, B-cell binding and cytotoxicity
K Laginha et al.
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES (2005)
A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity
D Lu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
A bispecific recombinant immunotoxin, DT2219, targeting human CD19 and CD22 receptors in a mouse xenograft model of B-cell leukemia/lymphoma
DA Vallera et al.
CLINICAL CANCER RESEARCH (2005)
B cells as a therapeutic target in autoimmune diseases other than rheumatoid arthritis
RJ Looney
RHEUMATOLOGY (2005)
Platelet-derived growth factor receptor (PDGFR): A target for anticancer therapeutics
R Board et al.
DRUG RESISTANCE UPDATES (2005)
A bispecific immunotoxin (DTAT13) targeting human IL-13 receptor (IL-13R) and urokinase-type plasminogen activator receptor (uPAR) in a mouse xenograft model
DA Todhunter et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2004)
Simultaneous blockade of both the epidermal growth factor receptor and the insulin-like growth factor receptor signaling pathways in cancer cells with a fully human recombinant bispecific antibody
D Lu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Passive antibody therapy for infectious diseases
A Casadevall et al.
NATURE REVIEWS MICROBIOLOGY (2004)
Inhibition of allergen-specific IgE reactivity by a human Ig Fcγ-Fcε bifunctional fusion protein
K Zhang et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2004)
Vascular endothelial growth factor: Basic science and clinical progress
N Ferrara
ENDOCRINE REVIEWS (2004)
Future directions of liposome- and immunoliposome-based cancer therapeutics
JW Park et al.
SEMINARS IN ONCOLOGY (2004)
A bispecific antibody against human IgE and human FcγRII that inhibits antigen-induced histamine release by human mast cells and basophils
SW Tam et al.
ALLERGY (2004)
The effect of variable domain orientation and arrangement on the antigen-binding activity of a recombinant human bispecific diabody.
D Lu et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2004)
Di-diabody: a novel tetravalent bispecific antibody molecule by design
D Lu et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2003)
Interaction of differently designed immunoliposomes with colon cancer cells and Kupffer cells.: An in vitro comparison
GA Koning et al.
PHARMACEUTICAL RESEARCH (2003)
Chemically programmed monoclonal antibodies for cancer therapy: Adaptor immunotherapy based on a covalent antibody catalyst
C Rader et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
ErbB2 overexpression correlates with increased expression of vascular endothelial growth factors A, C, and D in human breast carcinoma
WT Yang et al.
CANCER (2002)
A new model for intermediate molecular weight recombinant bispecific and trispecific antibodies by efficient heterodimerization of single chain variable domains through fusion to a Fab-chain
R Schoonjans et al.
BIOMOLECULAR ENGINEERING (2001)
Angiogenesis in cancer and other diseases
P Carmeliet et al.
NATURE (2000)
Share Paper
